Sanofi will lower the catalog price of insulin sold in the United States, Lantus, by 78%. The French pharmaceutical group will also set a ceiling of 35 dollars (33 euros) on the remainder to be paid for this drug for all patients benefiting from health insurance.
This decision comes as the American laboratory Eli Lilly announced earlier this month that it would reduce the price of its most commonly prescribed insulin in the United States by 70% from the fourth quarter.
VOS INDICES
source
US lawmakers are criticizing healthcare companies for skyrocketing insulin costs in recent years. The Inflation Reduction Act, signed by President Joe Biden, caps the remainder payable by Medicare-insured patients at $35.
Sanofi will also reduce the list price of its short-acting insulin Apidra by 70%, the group said in a press release.
With Archyde.com (Camille Raynaud)
